Reviva Pharmaceutcls Hldgs Inc Stock Price, News & Analysis

Reviva Pharmaceuticals Holdings (NASDAQ: RVPH) announces that CEO Laxminarayan Bhat will present at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The presentation is scheduled for May 25 at 3:00 p.m. ET, available both in-person in Miami and through virtual one-on-one meetings. Reviva focuses on addressing unmet medical needs in CNS, cardiovascular, metabolic, and inflammatory diseases, with candidates RP5063 and RP1208 in their pipeline. For further details and registration, visit the conference's official website.

Reviva Pharmaceuticals (RVPH) reported a net loss of approximately $7.4 million or $0.40 per share for Q1 2022, an increase from $0.9 million or $0.10 per share in Q1 2021. As of March 31, 2022, cash reserves totaled $23.4 million, down from $29.7 million at year-end 2021, but projected to fund operations until at least March 2023. The company has initiated a pivotal Phase 3 trial for its lead asset, brilaroxazine, targeting schizophrenia. Topline data is expected in mid-2023.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) announced positive progress in its Phase 3 RECOVER study for brilaroxazine, a treatment for acute schizophrenia. All U.S. clinical sites are active, with global sites in Europe and India to initiate mid-2022. The study involves approximately 400 patients, assessing safety and efficacy with no serious treatment-related adverse events reported to date. Results are expected in mid-2023, which could significantly impact Reviva’s market position and future growth.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) will host a key opinion leader (KOL) webinar on brilaroxazine (RP5063) for schizophrenia and neuropsychiatric disorders on May 3, 2022 at 10:00 AM ET. The event will cover unmet medical needs in these areas and feature experts Leslie Citrome, MD, and Larry Ereshefsky, PharmD. Reviva’s CEO, Dr. Laxminarayan Bhat, will present clinical data supporting the Phase 3 evaluation of brilaroxazine, a potential treatment targeting serotonin and dopamine receptors implicated in schizophrenia.

Reviva Pharmaceuticals Holdings (NASDAQ: RVPH) announced an upcoming interview with CEO Dr. Laxminarayan Bhat on The RedChip Money Report®, airing on Bloomberg TV at 7 p.m. ET on March 26, 2022. The segment, aimed at investors, covers small-cap market insights and features executive interviews. Reviva focuses on developing therapies for unmet medical needs in central nervous system, respiratory, and metabolic diseases, with two proprietary drug candidates, RP5063 and RP1208, both secured with composition of matter patents in multiple markets.

Reviva Pharmaceuticals Holdings (NASDAQ: RVPH) announced that Laxminarayan Bhat, Ph.D., its Founder and CEO, will participate in the Maxim Virtual Growth Conference from March 28-30, 2022. Bhat is scheduled for a fireside chat on March 30 at 1:00 pm ET. Reviva is focused on developing therapies for unmet medical needs in CNS, cardiovascular, metabolic, and inflammatory diseases. The company's pipeline includes two drug candidates, RP5063 and RP1208, which have received patent protection in multiple regions.

Reviva Pharmaceuticals (NASDAQ: RVPH) announced that its Founder and CEO, Laxminarayan Bhat, will participate in the 5th Annual Neuroscience Innovation Forum on March 23, 2022, and BIO-Europe Spring from March 28 to 31, 2022. Both events will feature corporate presentations available on demand, with opportunities for one-on-one meetings. Reviva focuses on developing therapies for CNS, cardiovascular, metabolic, and inflammatory diseases, with notable drug candidates RP5063 and RP1208. The company emphasizes its commitment to addressing significant unmet medical needs.

Reviva Pharmaceuticals Holdings (RVPH) reported a net loss of $8.5 million for 2021, equating to $0.58 per share, an increase from $3.8 million in 2020. As of December 31, 2021, the company had $29.7 million in cash, sufficient to fund operations through at least December 2022. Key developments include the initiation of a pivotal Phase 3 trial for brilaroxazine aimed at treating schizophrenia, with topline data expected by mid-2023. The company also plans to explore additional indications and funding opportunities for future studies.

Reviva Pharmaceuticals (NASDAQ: RVPH) has initiated dosing in its pivotal Phase 3 RECOVER trial for brilaroxazine, targeting acute schizophrenia. The trial aims to evaluate safety and efficacy in approximately 400 patients, with dosing set at 15 mg or 50 mg daily for 28 days. Following a successful Phase 2 study, Reviva plans to expand brilaroxazine's use to other neuropsychiatric conditions such as bipolar disorder and major depressive disorder. The FDA may consider a 'Superior Safety' label pending positive trial results, emphasizing the drug's potential in addressing significant treatment gaps in mental health.